Literature DB >> 8099844

Energy-dependent transport of digoxin across renal tubular cell monolayers (LLC-PK1).

S Ito1, G Koren, P A Harper, M Silverman.   

Abstract

Digoxin secretory transport across renal tubular cell monolayers (LLC-PK1) grown on permeable filters was characterized. Metabolic inhibitors reduced total and specific basolateral to apical (B-A) flux of digoxin and conversely increased the apical to basolateral (A-B) flux. The specific transport of digoxin from the basolateral to the apical compartment was saturable, with a maximum velocity of transport of 184.5 +/- 38.0 pmol.cm-2.h-1 and a Michaelis-Menten constant (Km) of 14.1 +/- 1.6 microM. In addition, B-A flux of digoxin resulted in accumulation of digoxin in the apical compartment against the concentration gradient. P-Glycoprotein inhibitors such as quinidine, verapamil, vincristine, and cyclosporine increased the net A-B flux and inhibited the total B-A flux without affecting the nonspecific flux significantly. Tetraethylammonium, a prototype substrate for an organic cation transport system, had no such effect. Our results suggest that digoxin undergoes transepithelial secretion by an energy-dependent, carrier-mediated process in renal tubules, a process that seems to be distinct from the tetraethylammonium transport system.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099844     DOI: 10.1139/y93-006

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  8 in total

1.  Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene.

Authors:  Nicole Soranzo; Gianpiero L Cavalleri; Michael E Weale; Nicholas W Wood; Chantal Depondt; Richard Marguerie; Sanjay M Sisodiya; David B Goldstein
Journal:  Genome Res       Date:  2004-06-14       Impact factor: 9.043

Review 2.  Drug exsorption from blood into the gastrointestinal tract.

Authors:  K Arimori; M Nakano
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

Review 3.  Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.

Authors:  Joseph D Ma; Shirley M Tsunoda; Joseph S Bertino; Meghana Trivedi; Keola K Beale; Anne N Nafziger
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

4.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

Authors:  B Greiner; M Eichelbaum; P Fritz; H P Kreichgauer; O von Richter; J Zundler; H K Kroemer
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

5.  Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation.

Authors:  G Fricker; J Drewe; J Huwyler; H Gutmann; C Beglinger
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

6.  Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells.

Authors:  M E Cavet; M West; N L Simmons
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

7.  Central nervous system (CNS) delivery of glucocorticoids is fine-tuned by saturable transporters at the blood-CNS barriers and nonbarrier regions.

Authors:  Brittany L Mason; Carmine M Pariante; Sara Jamel; Sarah A Thomas
Journal:  Endocrinology       Date:  2010-09-29       Impact factor: 4.736

8.  The influence of bariatric surgery on oral drug bioavailability in patients with obesity: A systematic review.

Authors:  Philip Carlo Angeles; Ida Robertsen; Lars Thomas Seeberg; Veronica Krogstad; Julie Skattebu; Rune Sandbu; Anders Åsberg; Jøran Hjelmesaeth
Journal:  Obes Rev       Date:  2019-06-24       Impact factor: 9.213

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.